
Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement under Nasdaq Rules
Moleculin Biotech Announces Registered Direct Offering and Concurrent Private Placement Houston, TX, February 25, 2025 – Moleculin Biotech, Inc. (NASDAQ: MBRX), a biotech company specializing in the development of drugs for hard-to-treat tumors and viruses, recently announced a securities purchase agreement with an institutional investor. This agreement pertains to a registered direct offering and a…